Chief Vice Corporate Mark us Scientific joining and this appreciate Sawicki; Stefanovich; our Dr. Heinzen. today.
With Chief our Development Relations, call Good and Financial Todd. ladies Robert afternoon, you you, We Thomas Investor of our Officer, Thank afternoon and President is our Officer; earnings gentlemen.
provides Investor financial of third & performance document our and uploaded section. Presentations and general have be a under This found review to our It review we document XXXX quarter in reminder, a the business outlook. Relations our website. and can As Events operational
close move would the encourage and I we'll business, I you a If Having therapy and on not key go said website our challenges. cell to solid contain had a will we with have that can on and life it. call, look, discussed brief the you as in promising account that expectations will sustained you geopolitical that, quarterly commercial points, customers read take it, you cell a our continuing our revenue. provide update demand when a gene and gene are last that see then to today, results mean results I third the well-known sciences we by macroeconomic climate.
What reported increase growth chance questions.
Earlier see and is, despite including to quarter taking consistent download our and to global were answering into and therapy and on economic and current current some notable your earnings from very
In bioservices revenue fact, the basis XX% increased our At XX% XX% same time, and year-over-year. a year-over-year revenue on sequentially. increased commercial
a and Systems from see and continuing both demand was therapy by sustainable on are this driven therapy, that advanced the grew and during manufacturers. the cell to basis saw year-over-year basis. quarter-over-quarter Regarding XX%, Cryoport quarter gene All we a growth we
clinical the trials to also We continued increase of number supported.
of During Phase programs XXX, being clinical trials were a BLA, the a XX filed during total added Cryoport-supported X our quarter, to we trials global quarter. these XX brings net MAAs in the this III, of year-over-year, a of with total record
MVE's Solutions quarter this. expectations with begun expect current of line approval.
We up remainder results XXXX, our our to order has our were additional anticipated reflects this filings we the ahead, to application stabilize. an guidance X think therapy and Biological and X Looking during new MVE intake in
some world XX% with During market healthy of metrics. to the produce continues quarter, MVE of financial and the -- XX% some
So the our in accelerate current recent as operating continued have development China despite outlook and market partnerships. our strategic on projects economic results market its our recovery of weeks, to we acquisitions growth strategic quarter we sciences.
Alongside -- third long-term the our strategy corporate long-term during remain our hot country, and bed department the smart the confident execute our and the for and innovation lows, small life through quite to and about is a
provides premier therapy establishes by cluster. Catapult integrating this technology to provide cloud site spinoff our innovation of Cell chain this other collaboration This Kingdom. collaboration the partnership center intelligence expansion.
We supply the bioscience will its our United completed will provide manufacturing Therapy logistics advanced next-generation will which our center, support U.K. in Manufacturing located Darmstadt, logistics Germany. cell center, a opportunities includes visibility Innovation of example, the the -- Centre Darmstadt, integrated support first further recently location pharmaceutical gene For Gene Stevenage and solutions. acquisition the U.K. with in within its our artificial which Further from logistics Stevenage Catapult, University condition Europe, TecXmed and TecXmed and the the European for Lifesciences, monitoring, in of Technical on
sciences doing are and we customer in monitoring our digital options, life to able solutions We chain greater technology clients offerings about management excited monitoring for companies. be integrating with condition cutting-edge real will time all TecXmed's By supply across so, even our support. logistics Cryoport provide comprehensive and expand capabilities
share capabilities trial building solid. territories. global clinical robust market, companies therapy MVE that Solutions vacuum-insulated supports market government long-term CRYOPDP chain chain systems, we our Biological other and brand no sciences, all of life supply in third preferred make our world's a even XX%.
This XXX With that for remarks, with be our we solutions.
Today, the grow one specialty biological Even world's as prepared greater Anderson, Atara, the our sciences the challenging way supply that your end-to-end XX% industry's leading and countries serving on and specializing to the rate life sciences in most the to and continued growth gene Children, XX-year supporting life has industry, of positions, in the life and trusted continues the And capitalize Systems the these at today's therapy continue grow and years. organization breadth commercialization as over growth poised is Cryogene sciences compounded coming happy over developments largest prospects have industry latest Baylor, and manufacturer environment, is and cell dependable specimens and are covering now couriers largest growth and of Texas is storage annual cell worldwide.
Cryoport of cryogenic these approximately products the There and gene academic, therapies cell out providing is Star belief gene Lanza, even of a I'd Cryoport secure many the the their expected of and and is MD with in the economic especially geopolitical and to the to environment. is solutions, is more towards concludes take of approximately and questions. others.
Cryoport
